Helping you individualize immunotherapies

 

Your work to develop novel immunotherapies is leading the way toward a future with better outcomes in the fight against cancer. Whether you’re leveraging the latest scientific insights to develop vaccines, gene therapies, T cell therapies, or monoclonal antibodies, you’re helping to usher in a new era in oncology.

To help ensure the efficacy of new treatments and their successful commercialization, you need to implement high-quality and cost-effective research tools at every step of the workflow, from novel target identification to T cell isolation, engineering, and expansion.

We help our customers stay a step ahead on the path to precision medicine. When you partner with us, our scientific expertise and broad portfolio of innovative research tools are at your fingertips, meeting your every need from discovery to commercialization. As the world leader in serving science, we’re the right partner to help you accelerate your breakthrough innovations to market so that you can make a life-changing difference for those who need it most.

 

The importance of immunotherapy

 

Immunotherapies work by enabling the immune system to recognize and attack cancer cells. They are currently the first-choice solution to treat many types of cancer. Types of immunotherapies include:

  • Checkpoint inhibitors (CPI), which block the immune suppressive interaction of a protein on the surface of a cancer cell (i.e., programmed death ligand 1, or PD-L1) with its receptor on a T cell (i.e., programmed cell death protein 1, or PD-1), enabling the immune response to proliferate.
  • Adoptive or CAR T cell therapy, which is currently used to treat children with acute lymphoblastic leukemia (ALL) and certain types of B cell lymphomas, and involves engineering a cancer patient’s T cells to express a synthetic chimeric antigen receptor, or CAR, in order to render cancer cells vulnerable to their attacks. CARs possess the unique ability to bind to cancer cells regardless of whether or not an antigen has been presented to a T cell.

Because they are personalized (in the sense that they leverage a patient’s own immune system to treat the cancer), these and other immunotherapies have the potential to accomplish some of the longest-held aspirations by those whose goal is to improve outcomes for cancer patients: to develop therapies that are more effective, less invasive, and have fewer side effects.

 

Our solutions in immunotherapy

 

Style Sheet for Global Design System